SARS-CoV-2 mucosal neutralising immunity is enhanced by vaccination and infection

Edward J Carr1,2, Guilia Dowgier\*,3, David Greenwood\*,2, Lou S Herman\*,3, Agnieszka Hobbs\*,3, Martina Ragno\*,3, Phoebe Stevenson-Leggett3, Joshua Gahir2,8, Hermaleigh Townsley2, Ruth Harvey4, Chris Bailey2, Ashley S Fowler2, Murad Miah2, Callie Smith2, Mauro Miranda2, Philip Bawumia2, Harriet V Mears2, Lorin Adams4, Emine Hatipoglu2,9, Nicola O’Reilly2, Scott Warchal2, Chelsea Sawyer2, Karen Ambrose2, Amy Strange2, Gavin Kelly2, Rupert Beale1,2,10, Padmasayee Papineni5, Tumena Corrah5, Richard Gilson6,9, Steve Gamblin2, George Kassiotis2,7, Vincenzo Libri8,9, Bryan Williams8,9, Charles Swanton2,9, Sonia Gandhi2,9, David LV Bauer\*,2,10, Emma Wall\*,2,8, and Mary Y Wu\*,2,3,✉

\* These authors contributed equally to this work.

1 UCL Dept of Renal Medicine, Royal Free Hospital, Rowland Hill Street, London, NW3 2PF  
2 The Francis Crick Institute, 1 Midland Road, London NW1 1AT  
3 COVID Surveillance Unit, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT  
4 Worldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT  
5 London Northwest University Healthcare NHS Trust, London  
6 Central and North West London NHS Foundation Trust, London  
7 Department of Infectious Disease, St Mary’s Hospital, Imperial College London, London  
8 National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London  
9 University College London, London, UK  
10 Genotype-to-Phenotype UK National Virology Consortium (G2P-UK)

✉ Correspondence: [Mary Y Wu <mary.wu@crick.ac.uk>](mailto:mary.wu@crick.ac.uk)

Word count 897.

# Main text

Mucosal vaccines that prevent SARS-CoV-2 infection may provide benefits beyond existing intramuscularly administered vaccines: through enhanced individual-level protection against disease, and through population-level reduction of viral carriage and transmission. Secreted neutralising antibodies are likely to be the crucial effectors for such mucosally-directed vaccines1. However, it is presently unclear to what extent intramuscular administration of Covid-19 vaccines enhances neutralising antibody titres in the mucosal compartment, nor the breadth of variants that are neutralised.

In response to this, we now describe an adapted version of our high-throughput live-virus microneutralisation assay for mucosal samples and use it to determine the effect of fourth-dose intramuscular mRNA vaccination on neutralising antibodies against 6 SARS-CoV-2 variants (Omicron BA.1, BA.2, BA.5, BQ.1.1, XBB.1.5, XBB.1.16) in paired serum and mucosal samples from 149 participants (Table 1)2 enrolled in the University College London Hospital and Francis Crick Institute Legacy study (NCT04750356)2–6. Mucosal samples were self-collected nasopharyngeal swabs into viral transport media (VTM). The Legacy study was approved by London Camden and Kings Cross Health Research Authority Research and Ethics committee (20/HRA/4717).

We found that intramuscular administration of a bivalent (Ancestral + BA.1) mRNA vaccine enhances mucosal neutralising activity (Figure A & Supplementary Figure 1), even when stratified by anti-nucleocapsid (anti-N) IgG negative and positive serostatus (previously un-infected or infected, respectively; Figure B). This boost appears restricted to variants closely related to the administered Spikes, with significant enhancement for BA.1 irrespective of previous infection status (*P*=0.02 and *P*=0.032 in anti-N IgG negative and positive groups, respectively), and without significantly improving neutralising capacity against more recently circulating and antigenically distant variants in either group (BQ.1.1 *P*=0.091 & *P*=0.32; XBB.1.5 *P*=0.058 & *P*=0.22; XBB.1.16 *P*=0.66 & *P*=0.25, respectively). Intriguingly, individuals with equivalent numbers of Spike exposures have similar levels of mucosal neutralising antibodies (4 exposures: [anti-N IgG- after dose 4] vs [anti-N IgG+ before dose 4]; BA.1 *P*=0.18; BA.2 *P*=0.32; BA.5 *P*=0.55; BQ.1.1 *P*=0.85; XBB.1.5 *P*=0.93; XBB.1.16 *P*=0.18). Additionally, we found that mucosal binding RBD immunoglobulins were higher in the anti-N IgG- group, compared to those with prior infection, albeit with a small absolute increase (3 doses & anti-N IgG+15.1 [8.24-46.7] vs 4 doses & anti-N IgG-25.3 [18.3-52]median [IQR]; *P*=0.046). Together, the mucosal antibody compartment appears reminiscent of our serological findings7, where the number of Spike encounters was the critical determinant of neutralising titres.

To dissect which antibody isotype might contribute to the boosting of mucosal neutralisation capacity, we measured the concentrations of total IgA and IgG in VTM samples (Figure C). We found that IgA contributed much more to the mucosal immunoglobulin compartment than IgG (median fold-change [IQR]; pre 20.5 [9.8-53.3]; post 21.6 [12.5-81.2]), and that neither isotype was boosted after vaccination (Figure C, IgA *P*=0.665; IgG *P*=0.061). However, we did detect a post-vaccine increase in immunoglobulins that bound Ancestral RBD, present in individuals with and without prior infection (Figure D, anti-N IgG- *P*=9.4x10-7; anti-N IgG+ *P*=0.0064), using anti-N IgG serostatus to stratify prior infections. At a population-level, anti-Ancestral RBD antibody concentrations were positively correlated with variant-specific mucosal neutralisation (Figure E). These Ancestral RBD binding: per variant neutralisation relationships weaken with more antigenically distinct variants, and in those without prior infection.

Next, we determined if there are relationships between serum and mucosal neutralisation (Supplementary Figure 2). We find positive correlations between serum and mucosal samples before dose 4 for BA.1, BA.2, BA.5 and BQ.1.1 (*P*=0.00025, *P*=0.00021, *P*=0.0025, *P*=0.0015 respectively) but not the more recent variants XBB.1.5 or XBB.1.16 (*P*=0.14, *P*=0.23). After dose 4, there are no significant correlations between serum and mucosal neutralisation suggesting these compartments are differentially boosted. Within the pre-dose 4 comparisons, stratified by the presence of anti-N IgG, the correlations are predominantly driven by the previously infected individuals (Supplementary Figure 2A). Taken together, these observations suggest a weaker, relationship between serum and mucosal neutralising immunity in uninfected individuals.

In summary, we have described a high-throughput method for live-virus microneutralisation using nasopharyngeal sampling into VTM and report several findings with broad application. Nasopharyngeal self-swabbing into VTM has advantages of being an easy and economical method of sampling the upper respiratory compartment, avoiding proprietary sampling strips and allowing repurposing of swabs used for viral testing and isolation. Importantly, parenteral vaccination boosts total mucosal neutralising capacity. Since this boost occurs in individuals both with and without prior mucosal challenge from infection, our data argue against a closed system of mucosal immunity only triggered by a mucosal challenge, such as infection8. Similarly, we identified a positive correlation between serum and mucosal neutralisation that was most apparent in previously-infected individuals, thus demonstrating that infection propagates antibody in both serum and mucosal compartments, and arguing against large mucosal-only locally produced antibody after infection9. Furthermore, similar levels of mucosal neutralisation after equivalent number of Spike exposures, whether via infection or vaccination, suggest that further boosting via intramuscular vaccines can enhance mucosal neutralising capacity further and potentially broaden the capacity as we have seen in the serum compartment. Identifying the sources for these mucosal neutralising antibodies will be the next steps (see supplementary discussion). Ongoing large cohort studies will offer the opportunity to dissect this further and provide insights relevant to the adjudication of the best mono- or multi-valent formulations for vaccines targeting mucosal immunity. Indeed, the VTM sampling approach described here enables large-scale sample collection and testing for mucosal neutralisation required for vaccine evaluation10, and will allow further exploration of cross-compartment neutralisation — for both present and future-generation vaccines, including those directly targeting mucosal sites.

|  |
| --- |
| **Mucosal neutralising immunity against SARS-CoV-2 variants** **(A)** Mucosal neutralising immunity against BA.1, BA.2, BA.5, BQ.1.1, XBB.1.5 and XBB.1.16 measured before and after dose 4 **(B)** As in (A) stratified by prior infection using anti-nucleocapsid IgG **(C)** Mucosal concentrations of total IgA or IgG before and after dose 4 **(D)** Mucosal concentrations of Ancestral RBD binding immunoglobulin before and after dose 4 stratified by anti-nucleocapsid IgG **(E)** Scatterplots of neutralising immunity against BA.1, BA.2, BA.5, BQ.1.1, XBB.1.5 and XBB.1.16 against mucosal concentrations of Ancestral RBD binding immunoglobulin before and after dose 4. Anti-N IgG negative or positive individuals are plotted as circles or triangles respectively, with trendlines in full or dashed lines respectively. Spearman’s correlation coefficient and *P* value are shown (bottom: anti-N IgG negative [grey] or top: positive [black]) In (A-D), *P* values from 2-tailed unpaired Wilcoxon tests are shown. In (A, B and D), 25% neutralisation is marked with gray triangles, reflecting the distribution of VTM-only negative controls (Supplementary Figure 1). |

# Table 1

dat %>%  
 group\_by(elig\_study\_id) %>%  
 arrange(desc(calendar\_date)) %>%  
 slice\_head() %>%  
 ungroup() %>%  
 select(  
 sex, age, dose\_4, Roche\_N\_result  
 ) %>%  
 mutate(dose\_4 = factor(dose\_4)) %>%  
 mutate(cols = paste(dose\_4)) %>%   
 tbl\_summary(by=cols,  
 missing= "ifany",  
 statistic = all\_continuous() ~ "{median} [{p25}-{p75}]",  
 label = c(sex="Sex",dose\_4="Bivalent fourth dose",  
 age="Median age (years) [IQR]",  
 Roche\_N\_result="anti-N IgG at latest visit"  
   
 )  
 ) %>% add\_p(include = ! dose\_4) %>%  
 as\_gt(.)

# References

1 Marking U, Bladh O, Havervall S, *et al.* Mucosal IgA protects against BQ.1 and BQ.1.1 infection. *The Lancet Infectious Diseases* 2023; published online July 12. DOI:[10.1016/S1473-3099(23)00421-8](https://doi.org/10.1016/S1473-3099(23)00421-8).

2 Carr EJ, Wu MY, Gahir J, *et al.* [Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection](https://doi.org/10.1016/S1473-3099(23)00289-X). *The Lancet Infectious Diseases* 2023; **23**: 781–4.

3 Wall EC, Wu M, Harvey R, *et al.* [AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC](https://doi.org/10.1016/S0140-6736(21)01462-8). *Lancet (London, England)* 2021; **398**: 207–9.

4 Wall EC, Wu M, Harvey R, *et al.* [Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination](https://doi.org/10.1016/S0140-6736(21)01290-3). *Lancet (London, England)* 2021; **397**: 2331–3.

5 Wu M, Wall EC, Carr EJ, *et al.* [Three-dose vaccination elicits neutralising antibodies against omicron](https://doi.org/10.1016/S0140-6736(22)00092-7). *Lancet (London, England)* 2022; **399**: 715–7.

6 Townsley H, Gahir J, Russell TW, *et al.* COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history. DOI:[10.1101/2022.07.07.22277367](https://doi.org/10.1101/2022.07.07.22277367).

7 Carr EJ, Wu MY, Gahir J, *et al.* [Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection](https://doi.org/10.1016/S1473-3099(23)00289-X). *The Lancet Infectious Diseases* 2023; **23**: 781–4.

8 Tang J, Zeng C, Cox TM, *et al.* [Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination](https://doi.org/10.1126/sciimmunol.add4853). *Science Immunology* 2022; **7**: eadd4853.

9 Liew F, Talwar S, Cross A, *et al.* [SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination](https://doi.org/10.1016/j.ebiom.2022.104402). *eBioMedicine* 2022; **87**: 104402.

10 Singh C, Verma S, Reddy P, *et al.* [Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®)](https://doi.org/10.1038/s41541-023-00717-8). *NPJ vaccines* 2023; **8**: 125.

# Appendix

## Supplementary Figure 1

|  |
| --- |
| **Mucosal neutralisation assay validation** **(A)** Neutralisation for nine VTM-only control wells of a 96 well plate. Each control well is run in quadriplicate in 384 well assay plate, shown is the median per plate value. Neutralisation is expressed as a percentage of inhibition of viral infection **(B)** Neutralisation of nanobody control at serial dilutions decreasing A11 to F11. As in A, the median from four technical repeats per plate is shown. **(C)** Robust coefficient of variation, RCV[Q], from VTM samples. RCV[Q] was calculated across all of the 4 technical replicates is plotted against their median summarised mucosal neutralisation. RCV[Q] = 0.75 x IQR/median. **(D)** Mucosal neutralisation capacity, as in main figure A, scaled by mucosal IgA concentration. Scaling was performed as follows: (% neutralising activity)/log10[IgA], with IgA concentration expressed in mcg/mL. **(E)** Scaled Mucosal neutralisation capacity, as in D, restricted to paired pre and post swabs. In (D), *P* values from 2-tailed unpaired Wilcoxon tests, and the number of mucosal swabs tested shown. In (E), *P* values from 2-tailed Wilcoxon signed-rank (paired) tests, and the number of mucosal swabs tested shown. |

## Supplementary Figure 2

|  |
| --- |
| **Comparison between mucosal and serological neutralising immunity** **(A and B)** Scatterplots between serum neutralisation and mucosal neutralisation against BA.1, BA.2, BA.5, BQ.1.1, XBB.1.5 and XBB.1.16 before **(A)** or after **(B)** dose 4. Serum anti-N IgG negative or positive serum samples are shown as circles or triangles respectively. Spearman’s correlation coefficient and *P* value are shown (top=whole study; bottom=anti-N IgG negative [grey] or positive [black], using only data within the quantitative range for serum [40-2560]). **(C)** As in Figure A, using paired mucosal samples pre- and post- fourth doses. *P* values are from 2-tailed Wilcoxon signed-rank (paired) tests, and the number of mucosal swabs tested shown. |